This diagnostic trial seeks to help patients with smoldering multiple myeloma (SMM) take control of monitoring their disease. Roughly 50% of patients with SMM will progress to active disease within 5 years from diagnosis, 7% of whom will progress to light chain amyloidosis (AL). AL is a disease where plasma cells produce light chains that misfold and can accumulate throughout the body and cause organ dysfunction. AL is frequently overlooked as a diagnosis, which allows more time for harmful proteins to build up in different organs, making the disease much harder to treat. One of the most effective ways you can take control of your disease is taking active measures to catch any signs of progression as early as possible.